2 news items
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
MDNAF
3 Jun 24
; an Empowered Superkine targeting the IL-4R) in unresectable rGBM at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
MDNAF
22 May 24
partnering and investment activities surrounding the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting being held in Chicago from May
- Prev
- 1
- Next